Skip to main content

Table 5 Clinical response measures

From: Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

  Median day 0 (n = 30) Median day 134 (n = 21) Median improvement persistent responders (n = 16) Median improvement transient/non-responders (n = 5)
Tender joint count 13 2 70% 44%
Swollen joint count 9 6 49% 40%
Patient global assessment 44.0 9.0 67% 25%
Patient pain 52.0 23.0 65% 9%
Physician global assessment 45.5 24.5 61% 20%